ReviewOrphanet journal of rare diseases2025

Concurrent nanotherapeutics and regulatory updates for the management of amyotrophic lateral sclerosis: a focused review for orphan drug (Tofersen).

Abhiram Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.